Related Experiment Video
Updated: Feb 19, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
Anemia in Heart Failure: Still Relevant?
Niels Grote Beverborg1, Dirk J van Veldhuisen1, Peter van der Meer1
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
JACC. Heart Failure
|November 13, 2017
Summary
Anemia in heart failure patients is common and linked to worse outcomes. Current treatments like erythropoiesis-stimulating agents (ESAs) are not recommended due to risks and lack of clinical benefit.
Area of Science:
- Cardiology
- Nephrology
- Hematology
Background:
- Anemia affects one-third of heart failure patients, correlating with increased symptoms, hospitalizations, and mortality.
- The causes of anemia in heart failure are complex and multifactorial, including renal issues, bone marrow problems, medications, and nutritional deficiencies like iron deficiency.
Purpose of the Study:
- To review the pathophysiology of anemia in heart failure.
- To explain the limitations of current therapies, specifically erythropoiesis-stimulating agents (ESAs).
- To discuss promising future therapeutic strategies for anemia in heart failure.
Main Methods:
- Literature review focusing on the pathophysiology of anemia in heart failure.
- Analysis of the efficacy and safety of erythropoiesis-stimulating agents (ESAs) in heart failure patients.
- Exploration of emerging therapeutic targets and agents.
Main Results:
- Erythropoiesis-stimulating agents (ESAs) effectively raise hemoglobin levels but do not improve clinical outcomes in heart failure.
- The use of ESAs is associated with increased risks of thromboembolic events and ischemic stroke.
- The effectiveness of ESAs raises questions about whether anemia is a treatable target or a marker of disease severity.
Conclusions:
- Current evidence does not support the use of ESAs for treating anemia in heart failure due to safety concerns and lack of clinical benefit.
- Future therapies targeting the erythropoietin receptor, hepcidin pathway, or iron availability show promise.
- Further research is needed to determine optimal therapeutic strategies for anemia in heart failure.
Related Concept Videos
01:27Heart Failure I: Introduction
987
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
987
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:30Heart Failure VII: Nursing Interventions
559
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
559
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:26Imbalances in Cardiac Output
3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
01:26Heart Failure III: Clinical Manifestations
658
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
658